IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.

News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Market Closed - Hong Kong S.E. Other stock markets 04:08:07 2024-05-09 am EDT			5-day change	1st Jan Change
14.9 ^HKD	-0.53%		+1.09%	-50.17%

Apr. 17	ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication	MT
Apr. 17	ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication	Apr. 17	MT
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01	Apr. 17	CI
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases	Mar. 26	MT
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Immuneonco Biopharmaceuticals CFO Resigns	Mar. 03	MT
Immuneonco Biopharmaceuticals Inc. Announces Board and Executive Changes	Mar. 01	CI
ImmuneOnco Begins Phase II Clinical Trial of Anti-Tumor Drug	Nov. 20	MT
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma	Nov. 19	CI
ImmuneOnco Biopharmaceuticals Gets US FDA's Orphan-Drug Designation for Leukemia Drug Combination	Nov. 09	MT
ImmuneOnco Biopharmaceuticals Gets Nod to Trial Cancer Drug	Nov. 07	MT
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China	Nov. 07	CI
ImmuneOnco to Present Results of Anti-Cancer Drug Studies at American Convention	Nov. 06	MT
China Grants Investigational New Drug Approval to ImmuneOnco's Cancer Treatment; Shares Fall 4%	23-10-16	MT
ImmuneOnco Biopharmaceuticals Inc. Obtains an Investigational New Drug Approval for IMM47 for the Treatment of Solid Tumors from the National Medical Products Administration of the People's Republic of China	23-10-16	CI
ImmuneOnco to Raise Near HK$17 Million from Over-Allotment of Shares	23-09-29	MT
Immuneonco Biopharmaceuticals Inc. Provides Updates on the Clinical Trial of Imm47	23-09-27	CI
ImmuneOnco Biopharma Completes Patient Enrollment for Phase 1 Study of Two Antitumor Medications	23-09-12	MT
ImmuneOnco Biopharmaceuticals Inc. Provides Updates on the Clinical Trials of IMM2510 and IMM27M	23-09-11	CI
Hong Kong Stocks Retreat On Fears Over China Property Default; ImmuneOnco Biopharmaceuticals Gains 5%	23-09-05	MT
ImmuneOnco Biopharmaceuticals Inc. has completed an IPO in the amount of HKD 318.93792 million.	23-09-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Summary

Filters